Profile data is unavailable for this security.
About the company
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, and hemorheologic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, and NSAID. Its crop protection products are used in algaecide, biocide, fungicide, herbicide, insecticide, and intermediate. It offers contract research services for synthesis, process development, and manufacturing projects.
- Revenue in INR (TTM)16.99bn
- Net income in INR101.00m
- Incorporated1988
- Employees2.06k
- LocationHikal LtdGreat Eastern ChambersSector 11, CBD-BelapurNAVI MUMBAI 400614IndiaIND
- Phone+91 2 230973100
- Fax+91 2 227574277
- Websitehttps://www.hikal.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indoco Remedies Ltd | 17.58bn | -1.14bn | 18.67bn | 6.05k | -- | -- | 292.20 | 1.06 | -12.52 | -12.52 | 197.86 | -- | -- | -- | -- | 2,905,519.00 | -- | 4.84 | -- | 6.87 | 71.18 | 65.70 | -6.62 | 5.16 | -- | -0.3334 | -- | 17.11 | -8.38 | 8.51 | -174.89 | -- | 43.53 | -7.79 |
| Morepen Laboratories Ltd | 17.87bn | 994.48m | 21.12bn | 1.81k | 21.24 | -- | 14.33 | 1.18 | 1.81 | 1.81 | 32.65 | -- | -- | -- | -- | 9,850,214.00 | -- | 8.14 | -- | 12.81 | 33.71 | 31.83 | 5.61 | 5.91 | -- | 5.59 | -- | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
| Panacea Biotec Ltd | 6.04bn | -72.40m | 21.44bn | 1.29k | -- | 2.59 | 81.72 | 3.55 | -1.18 | -1.18 | 98.44 | 134.92 | 0.4836 | 1.38 | 8.67 | 4,681,039.00 | -0.6085 | 13.08 | -0.8291 | 19.61 | 58.47 | 48.06 | -1.26 | 30.99 | 0.9785 | -14.33 | 0.0271 | 0.00 | -0.0132 | 0.5466 | -613.56 | -- | 48.74 | -- |
| IOL Chemicals and Pharmaceuticals Ltd | 16.47bn | 953.20m | 21.94bn | 2.89k | 23.00 | -- | 14.27 | 1.33 | 3.25 | 3.25 | -- | -- | -- | -- | -- | 5,696,991.00 | -- | 10.26 | -- | 13.42 | 34.43 | 32.57 | 5.79 | 9.33 | -- | 8.05 | -- | 13.68 | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | 5.92 |
| Solara Active Pharma Sciences Ltd | 12.55bn | -191.10m | 22.08bn | 1.78k | -- | -- | 28.01 | 1.76 | -4.81 | -4.81 | 330.32 | -- | -- | -- | -- | 7,068,733.00 | -- | -3.27 | -- | -5.35 | 51.77 | 39.95 | -1.52 | -6.17 | -- | 0.7946 | -- | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| Bliss GVS Pharma Ltd | 8.68bn | 1.09bn | 23.04bn | 966.00 | 21.39 | -- | 15.65 | 2.65 | 10.18 | 10.18 | 80.97 | -- | -- | -- | -- | 8,986,598.00 | -- | 6.04 | -- | 7.54 | 52.65 | 46.33 | 13.18 | 9.45 | -- | 8.44 | -- | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Hikal Ltd | 16.99bn | 101.00m | 26.33bn | 2.06k | 259.88 | 2.20 | 16.29 | 1.55 | 0.8216 | 0.8216 | 137.81 | 96.86 | 0.7065 | 2.01 | 4.59 | 8,239,573.00 | 0.42 | 4.78 | 0.6016 | 7.00 | 55.49 | 48.00 | 0.5945 | 5.71 | 0.5418 | 1.11 | 0.3639 | 14.83 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
| Unichem Laboratories Ltd | 22.14bn | 2.95bn | 26.43bn | 3.33k | 8.98 | -- | 6.31 | 1.19 | 41.79 | 41.79 | 314.32 | -- | -- | -- | -- | 6,654,374.00 | -- | -0.5598 | -- | -0.6977 | 54.06 | 55.09 | 13.32 | -1.18 | -- | 3.47 | -- | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
| Gufic BioSciences Ltd | 8.74bn | 569.19m | 31.04bn | 1.99k | 54.51 | 4.92 | 36.57 | 3.55 | 5.68 | 5.68 | 87.10 | 62.94 | 0.7354 | 1.87 | 2.75 | 4,394,322.00 | 4.79 | 10.27 | 7.34 | 16.11 | 55.47 | 46.41 | 6.52 | 10.48 | 1.06 | 3.13 | 0.3691 | 1.31 | 1.63 | 16.69 | -19.14 | 25.15 | 13.64 | 14.87 |
| SMS Pharmaceuticals Ltd | 8.97bn | 895.91m | 31.57bn | 1.47k | 33.29 | -- | 25.15 | 3.52 | 10.13 | 10.13 | 101.51 | -- | -- | -- | -- | 6,102,851.00 | -- | 5.58 | -- | 7.66 | 32.55 | 33.78 | 9.71 | 8.05 | -- | 5.85 | -- | 5.72 | 10.36 | 13.70 | 38.75 | 16.97 | 23.62 | 9.86 |
| Dishman Carbogen Amcis Ltd | 27.97bn | 1.19bn | 31.63bn | 1.11k | 26.64 | -- | 7.06 | 1.13 | 7.57 | 7.57 | 178.50 | -- | -- | -- | -- | 25,287,880.00 | -- | -0.7247 | -- | -0.9005 | 84.96 | 74.27 | 4.25 | -2.77 | -- | 1.31 | -- | -- | 3.66 | 5.82 | 102.11 | -54.07 | -11.91 | -- |
| RPG Life Sciences Ltd | 6.74bn | 2.03bn | 32.66bn | 1.33k | 16.12 | -- | 14.60 | 4.85 | 122.51 | 122.51 | 407.37 | -- | -- | -- | -- | 5,061,758.00 | -- | 21.05 | -- | 27.78 | 64.34 | 63.28 | 30.07 | 16.68 | -- | 174.47 | -- | 24.92 | 12.26 | 11.71 | 109.03 | 44.58 | 27.39 | 37.97 |
| Orchid Pharma Ltd | 8.21bn | 522.57m | 33.70bn | 737.00 | 64.46 | 2.65 | 38.74 | 4.10 | 10.31 | 10.31 | 162.05 | 251.16 | 0.4893 | 1.58 | 3.94 | 11,143,480.00 | 3.10 | 1.40 | 3.63 | 1.72 | 39.83 | 35.89 | 6.33 | 2.75 | 1.90 | 2.18 | 0.181 | -- | 12.48 | 13.76 | 8.13 | -- | 104.06 | -- |
| Aarti Drugs Ltd | 25.22bn | 2.03bn | 33.93bn | 1.28k | 16.84 | -- | 12.74 | 1.35 | 22.07 | 22.07 | 274.99 | -- | -- | -- | -- | 19,639,960.00 | -- | 9.09 | -- | 14.39 | 36.35 | 22.09 | 8.03 | 8.08 | -- | 7.00 | -- | 6.07 | -5.60 | 5.74 | -1.90 | 3.53 | 29.85 | 14.87 |
| Gujarat Themis Biosyn Ltd | 1.59bn | 477.88m | 34.02bn | 221.00 | 71.20 | -- | 58.78 | 21.36 | 4.39 | 4.39 | 14.62 | -- | -- | -- | -- | 7,209,322.00 | -- | 30.70 | -- | 34.37 | 62.78 | 68.03 | 29.99 | 35.51 | -- | 55.73 | -- | -- | -11.20 | 12.12 | -17.56 | 15.55 | 104.61 | 24.95 |
Data as of Feb 13 2026. Currency figures normalised to Hikal Ltd's reporting currency: Indian Rupee INR
9.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 3.96m | 3.21% |
| Tata Asset Management Pvt Ltd.as of 31 Jan 2026 | 3.69m | 3.00% |
| Th�l�me Partners LLPas of 31 Dec 2025 | 1.35m | 1.09% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.06m | 0.86% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 978.50k | 0.79% |
| India Avenue Investment Management Australia Pty Ltd.as of 31 Jan 2026 | 216.19k | 0.18% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025 | 129.80k | 0.11% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 74.41k | 0.06% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 61.13k | 0.05% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 60.24k | 0.05% |
More ▼
Data from 30 Sep 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
